Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2

被引:25
作者
Itoh, T
Itagaki, S
Sumi, Y
Hirano, T
Takemoto, I
Iseki, K
机构
[1] Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Clin Pharmaceut & Therapeut, Kita Ku, Sapporo, Hokkaido 0600812, Japan
[2] Sapporo Social Insurance Gen Hosp, Dept Pharm, Atsubetsu Ku, Sapporo, Hokkaido 0048618, Japan
关键词
irinotecan; diarrhea; Caco-2; cells; baicalin;
D O I
10.1007/s00280-004-0937-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this study was to investigate the transport mechanisms of transporters that contribute to the intestinal uptake of 7-ethyl-10-hydroxycamptothecin (SN-38). Methods: Human intestinal epithelial Caco-2 cells were used to investigate the mechanistic basis of transepithelial uptake of SN-38. We investigated the characteristics of SN-38 uptake into Caco-2 cells. The effects of baicalin and sulfobromophthalein (BSP) on the uptake of SN-38 by Caco-2 cells were examined. Results: Uptake of SN-38 was significantly reduced at 4 degrees C. Baicalin inhibited the uptake of SN-38 in a concentration-dependent manner. BSP significantly reduced the uptake of SN-38. However, probenecid, pravastatin and grepafloxacin did not affect the uptake of SN-38. Conclusions: The results suggest that a specific transport system mediates the uptake of SN-38 across the apical membrane in Caco-2 cells.
引用
收藏
页码:420 / 424
页数:5
相关论文
共 23 条
[1]   IRINOTECAN (CPT-11) HIGH-DOSE ESCALATION USING INTENSIVE HIGH-DOSE LOPERAMIDE TO CONTROL DIARRHEA [J].
ABIGERGES, D ;
ARMAND, JP ;
CHABOT, GG ;
DACOSTA, L ;
FADEL, E ;
COTE, C ;
HERAIT, P ;
GANDIA, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (06) :446-449
[2]  
AKIMOTO K, 1994, CHEM PHARM BULL, V42, P2135, DOI 10.1248/cpb.42.2135
[3]   IDENTIFICATION OF THE METABOLITES OF IRINOTECAN, A NEW DERIVATIVE OF CAMPTOTHECIN, IN RAT BILE AND ITS BILIARY-EXCRETION [J].
ATSUMI, R ;
SUZUKI, W ;
HAKUSUI, H .
XENOBIOTICA, 1991, 21 (09) :1159-1169
[4]   Molecular features, regulation, and function of monocarboxylate transporters: Implications for drug delivery [J].
Enerson, BE ;
Drewes, LR .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (08) :1531-1544
[5]  
HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736
[6]   Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats [J].
Horikawa, M ;
Kato, Y ;
Sugiyama, Y .
PHARMACEUTICAL RESEARCH, 2002, 19 (09) :1345-1353
[7]  
HOUGHTON PJ, 1993, CANCER RES, V53, P2823
[8]  
Itagaki Shirou, 2003, Drug Metab Pharmacokinet, V18, P238, DOI 10.2133/dmpk.18.238
[9]  
Itoh T, 2004, J PHARM PHARM SCI, V7, P13
[10]   Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats [J].
Itoh, T ;
Itagaki, S ;
Sasaki, K ;
Hirano, T ;
Takemoto, I ;
Iseki, K .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (06) :809-812